KIT and gastrointestinal stromal tumor: Further, we document regorafenib clinical response in a patient whose GIST had a KIT activation loop imatinib-resistance mutation (Fig. 2b), supporting evidence we reported previously.23 Nonetheless, KIT activation loop secondary mutations are heterogeneous and the present study demonstrates variable regorafenib activity depending on the exact activation loop amino acid alteration.